Article
EGFR mutation status affects intra-tumoural heterogeneity of PD-L1 expression but not agreement between assays in resectable non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) - 1 Apr 2025
Saw Stephanie P L, Takano Angela, Zhou Siqin, Hlaing Nwe Oo, James Anne, Joseph Craig, Lai Gillianne G Y, Lim Darren W T, Kanesvaran Ravindran, Ang Mei-Kim, Ng Quan Sing, Jain Amit, Tan Wan Ling, Teh Yi Lin, Tan Aaron C, Ong Boon-Hean, Lim Tony K H, Yeong Joe P S, Tan Sze Huey, Tan Daniel S W
Abstract excerpt
BACKGROUND: The predictive value of PD-L1 to select patients for immunotherapy in resectable NSCLC remains imprecise, confounded by different assays used across trials and intra-tumoural heterogeneity (ITH). We sought to compare the concordance between 3 PD-L1 antibodies stratified by EGFR mutation status, evaluate ITH and implications on survival outcomes. METHODS: Tissue microarrays were constructed from stage...
Read the complete abstract on PubMedTopics
- Humans
- Carcinoma, Non-Small-Cell Lung
- B7-H1 Antigen
- ErbB Receptors